Please provide your email address to receive an email when new articles are posted on . Crinecerfont enabled many children with congenital adrenal hyperplasia (CAH ...

In addition to new medications to treat this enzyme deficiency, research is underway on easier hormone sampling and fixing the gene mutation that causes CAH.

Please provide your email address to receive an email when new articles are posted on . The FDA approved crinecerfont to treat patients with congenital adrenal hyperplasia. The drug directly reduces ...

SAN FRANCISCO -- Crinecerfont (Crenessity) may help improve metabolic profiles of adults and children with classic congenital adrenal hyperplasia (CAH), analyses of phase III CAHtalyst trial data ...

One-year data from CAHtalyst ™ Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia Results ...

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™ (crinecerfont). The ...

Credit: Shutterstock. Crinecerfort is an investigational, oral, selective corticotropin-releasing factor type 1 receptor (CRF1) antagonist. A phase 3 study evaluating the efficacy and safety of ...

In adults, open-label data showed a sustained steroid-reducing benefit with the oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, according to findings presented by Sonal Vaid, MD ...

The NDA submissions are for 2 formulations of crinecerfont: a capsule and an oral solution. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Applications (NDA) for ...

Children with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency require treatment with glucocorticoids, usually at supraphysiologic doses, to address cortisol insufficiency ...